Key result
Novel platelet chip under development may improve future thrombohemorrhagic risk assessment and antiplatelet therapy.
Why the study?
Platelet hyper-reactivity likely contributes to cardiovascular disease, but no standardized tests exist to evaluate platelet responsiveness.
Requires rigorous validation before clinical use; leaves open whether platelet gene profiling improves thrombohemorrhagic risk assessment or guides therapy.
Platelet hyper-reactivity is likely to play a role in cardiovascular disease, but there are no standardized tests to evaluate platelet responsiveness. A 'platelet chip' (a synthetic oligonucleotide microarray representing all platelet-restricted genes) is under development as a tool for high-throughput characterization of platelet-based bleeding and clotting disorders. In future, platelet gene profiling may be used to improve thrombohemorrhagic risk assessment and to guide antiplatelet therapy for patients at risk of cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Senzel et al. (2007) conducted a review in Cardiovascular disease. Platelet gene profiling (platelet chip) was evaluated. A synthetic oligonucleotide microarray (platelet chip) is under development to characterize platelet-based disorders and may improve future thrombohemorrhagic risk assessment and antiplatelet therapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: